Intrahepatic Cholangiocarcinoma

75

Pipeline Programs↗

36

Active Trials↗

36

Companies Involved↗

Intrahepatic Cholangiocarcinoma is a moderately active landscape with 75 programs across 36 companies. The most active players are EMD Serono Research & Development Institute, Inc., Bristol-Myers Squibb, Innovent Biologics (Suzhou) Co. Ltd.. 5 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

27/100

Mech. Concentration

12/100

Completion Rate

50/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

EMD Serono Research & Development Institute, Inc.

1 program

Bristol-Myers Squibb

2 programs

Innovent Biologics (Suzhou) Co. Ltd.

2 programs

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

2 programs

Pfizer

2 programs

Virogin Biotech Canada Ltd

1 program

Pipeline

Programs by Phase

Preclinical6

Envafolimab

Tracon Pharmaceuticals Inc.

Envatinib Plus Anti-PD(L)1

Ze-yang Ding, MD

Derazantinib

Basilea Pharmaceutica

Immunocheckpoint Inhibitor Therapy

The Central Hospital of Lishui City

Surufatinib、toripalimab、gemcitabine、oxaliplatin

Fudan University

Phase 12

Bintrafusp Alfa

EMD Serono Research & Development Institute, Inc.

Tremelimumab

AstraZeneca

Phase 256

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Gemcitabine

Johnson & Johnson

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Toripalimab

Coherus Oncology, Inc.

Phase 36

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TT-00420

TransThera Sciences (Nanjing), Inc.

Levamisole Hydrochloride

SWOG Cancer Research Network

Cisplatin and Gemcitabine

National University Hospital, Singapore

Oxaliplatin and Gemcitabine

Shanghai Zhongshan Hospital

Approved5

Carboplatin

Avyxa

Bortezomib

Shilpa Grover, MD, MPH

Melphalan

Apotex Inc.

Lenvatinib

Eisai

HAIC of OXA

Sun Yat-sen University

Analysis

Modality Breakdown

81%

Small molecule

72 of 89 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 89 classified programs, each share of the total. Modality classified for 100% of 89 pipeline programs.

Analysis

Trial Status

78

clinical trials

Recruiting23 · 29%

Unknown status23 · 29%

Completed9 · 12%

Not yet recruiting8 · 10%

Active, not recruiting5 · 6%

Terminated5 · 6%

Other5 · 6%

Clinical Trials

Trial Activity

78 trials

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Recruiting·—·Phase 4·NCT05124002·66 enrolled

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Recruiting·MMayo Clinic·Phase 1·NCT06058663·16 enrolled

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT06298968·38 enrolled

HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06858735·60 enrolled

Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting·TTongji Hospital·Phase 2·NCT06192797·36 enrolled

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

Recruiting·FFudan University·Phase 2·NCT04954781·25 enrolled

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Recruiting·FFudan University·Phase 2·NCT07070700·56 enrolled

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05967182·24 enrolled

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Recruiting·LLei ZHAO·Phase 2·NCT06296563·20 enrolled

HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Recruiting·HHutchmed·Phase 2/3·NCT04353375·235 enrolled

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Recruiting·—·Phase 2·NCT06728410·38 enrolled

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

Recruiting·—·Phase 2·NCT06664021·60 enrolled

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

Recruiting·FFudan University·Phase 2·NCT04299581·25 enrolled

Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)

Recruiting·FFudan University·Phase 2·NCT06860477·92 enrolled

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT05678270·70 enrolled

Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)